The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Proapoptotic Stimuli Induce Nuclear Accumulation of Glycogen Synthase Kinase-3β
Open accessAbstract
The goal of this study was to determine whether the intracellular distribution of the proapoptotic enzyme glycogen synthase kinase-3 beta (GSK-3 beta) is dynamically regulated by conditions that activate apoptotic signaling cascades. In untreated human neuroblastoma SH-SY5Y cells, GSK-3 beta was predominantly cytosolic, although a low level was also detected in the nucleus. The nuclear level of GSK-3 beta was rapidly increased after exposure of cells to serum-free media, heat shock, or staurosporine. Although each of these conditions caused changes in the serine 9 and/or tyrosine phosphorylation of GSK-3 beta, neither of these modifications was correlated with nuclear accumulation of GSK-3 beta. Heat shock and staurosporine treatments increased nuclear GSK-3 beta prior to activation of caspase-9 and caspase-3, and this nuclear accumulation of GSK-3 beta was unaltered by pretreatment with a general caspase inhibitor. The GSK-3 beta inhibitor lithium did not alter heat shock-induced nuclear accumulation of GSK-3 beta but increased the nuclear level of cyclin D1, indicating that cyclin D1 is a substrate of nuclear GSK-3 beta. Thus, the intracellular distribution of GSK-3 beta is dynamically regulated by signaling cascades, and apoptotic stimuli cause increased nuclear levels of GSK-3 beta, which facilitates interactions with nuclear substrates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Sutherland, C., Leighton, I. A., & Cohen, P. (1993) · Biochemical Journal · doi:10.1042/bj2960015 · Cited by 903
Hartigan, J. A., & Johnson, G. V. W. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.30.21395 · Cited by 141
Cited by
GSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768
Self-citationThe glamour and gloom of glycogen synthase kinase-3
Jope, R. S., & Johnson, G. V. W. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.12.004 · Cited by 1,517
Self-citationThe GSK3 hypothesis of Alzheimer’s disease
Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191
GSK-3-Selective Inhibitors Derived from Tyrian Purple Indirubins
Meijer, L., Skaltsounis, A.-L., Magiatis, P., Polychronopoulos, P., Knockaert, M., Leost, M., Ryan, X. P., Vonica, C. A., Brivanlou, A., Dajani, R., et al. (2003) · Chemistry & Biology · doi:10.1016/j.chembiol.2003.11.010 · Cited by 808
Beurel, E., & Jope, R. S. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.07.006 · Cited by 541
Self-citationGSK-3 as potential target for therapeutic intervention in cancer
McCubrey, J. A., Steelman, L. S., Bertrand, F. E., Davis, N. M., Sokolosky, M., Abrams, S. L., Montalto, G., D’Assoro, A. B., Libra, M., Nicoletti, F., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2037 · Cited by 508
GSK-3: Functional Insights from Cell Biology and Animal Models
Kaidanovich-Beilin, O., & Woodgett, J. R. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00040 · Cited by 485
Glycogen Synthase Kinase-3β: A Novel Regulator of Cardiac Hypertrophy and Development
Hardt, S. E., & Sadoshima, J. (2002) · Circulation Research · doi:10.1161/01.res.0000018952.70505.f1 · Cited by 438
Glycogen Synthase Kinase-3 (GSK3) in Psychiatric Diseases and Therapeutic Interventions
Jope, R., & Roh, M.-S. (2006) · Current Drug Targets · doi:10.2174/1389450110607011421 · Cited by 382
Self-citationGlycogen Synthase Kinase-3: a Putative Molecular Target for Lithium Mimetic Drugs
Gould, T. D., & Manji, H. K. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300731 · Cited by 375
Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3‐kinase activation
Bijur, G. N., & Jope, R. S. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02113.x · Cited by 331
Self-citationGSK-3 and tau: a key duet in Alzheimer’s disease
Sayas, C. L., & Ávila, J. (2021) · Cells · doi:10.3390/cells10040721 · Cited by 314
“, in the Wnt or the Hedgehog pathways [30,31]), subcellular localization [32,33] and”
BackgroundChen, G., Bower, K. A., Ma, C., Fang, S., Thiele, C. J., & Luo, J. (2004) · The FASEB Journal · doi:10.1096/fj.04-1551fje · Cited by 310
Retractedα‐Synuclein contributes to GSK‐3β‐catalyzed Tau phosphorylation in Parkinson's disease models
Duka, T., Duka, V., Joyce, J. N., & Sidhu, A. (2009) · The FASEB Journal · doi:10.1096/fj.08-120410 · Cited by 275
Direct, activating interaction between glycogen synthase kinase-3β and p53 after DNA damage
Watcharasit, P., Bijur, G. N., Zmijewski, J. W., Song, L., Zmijewska, A., Chen, X., Johnson, G. V. W., & Jope, R. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122062299 · Cited by 266
Self-citationGlycogen Synthase Kinase-3β (GSK3β) Binds to and Promotes the Actions of p53
Watcharasit, P., Bijur, G. N., Song, L., Zhu, J., Chen, X., & Jope, R. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305870200 · Cited by 262
Self-citationSong, L., De Sarno, P., & Jope, R. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206047200 · Cited by 256
Self-citationMcCubrey, J. A., Steelman, L. S., Bertrand, F. E., Davis, N. M., Abrams, S. L., Montalto, G., D'Assoro, A. B., Libra, M., Nicoletti, F., Maestro, R., et al. (2014) · Leukemia · doi:10.1038/leu.2013.184 · Cited by 255
Al-Khouri, A. M., Ma, Y., Togo, S. H., Williams, S., & Mustelin, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503045200 · Cited by 252
Xing, B., Li, Y.-C., & Gao, W.-J. (2016) · Brain Research · doi:10.1016/j.brainres.2016.01.005 · Cited by 196
Reddy, P. H. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.06.012 · Cited by 147
GSK3 and p53 - is there a link in Alzheimer's disease?
Proctor, C. J., & Gray, D. A. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-7 · Cited by 80
Farías, G. G., Godoy, J. A., Hernández, F., Avila, J., Fisher, A., & Inestrosa, N. C. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.016 · Cited by 59
Wang, S.-B., Venkatraman, V., Crowgey, E. L., Liu, T., Fu, Z., Holewinski, R., Ranek, M., Kass, D. A., O’Rourke, B., & Van Eyk, J. E. (2018) · Circulation Research · doi:10.1161/circresaha.118.312789 · Cited by 54
Aberrant GSK3β nuclear localization promotes AML growth and drug resistance
Ignatz-Hoover, J. J., Wang, V., Mackowski, N. M., Roe, A. J., Ghansah, I. K., Ueda, M., Lazarus, H. M., de Lima, M., Paietta, E., Fernandez, H., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016006 · Cited by 27
Metadata
- Authors
- Bijur, G. N., & Jope, R. S.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-10
- Volume
- 276
- Issue
- 40
- Pages
- 37436-37442
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2053692735
- Cited by
- 204
- References
- 4
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.